Windtree Therapeutics May Receive Up to $78.9 Million in License Agreement Payments
I'm PortAI, I can summarize articles.
Windtree Therapeutics Inc. announced it may receive up to $78.9 million in milestone payments from its licensee for acute pulmonary treatments under an amended global license agreement. The licensee will cover all development and commercialization costs. The treatments target respiratory distress syndrome in premature infants. Further details on the timing and receipt of payments will be provided as available.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments